(Q46668388)

24 December 2017

title

Zoledronic acid inhibits primary bone tumor growth in Ewing sarcoma (English)

1 reference

24 December 2017

1 reference

1 reference

Zhichao Zhou

1

1 reference

24 December 2017

Hui Guan

series ordinal

2

1 reference

24 December 2017

Xiaoping Duan

series ordinal

3

1 reference

24 December 2017

Eugenie S Kleinerman

series ordinal

4

1 reference

24 December 2017

language of work or name

English

0 references

publication date

1 October 2005

1 reference

24 December 2017

published in

Cancer

1 reference

24 December 2017

volume

104

1 reference

24 December 2017

issue

8

1 reference

24 December 2017

page(s)

1713-1720

1 reference

24 December 2017

The anti-tumour activity of bisphosphonates.

cites work

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21383

7 January 2021

The anti-tumor potential of zoledronic acid

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21383

7 January 2021

Bisphosphonates: preclinical review

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21383

7 January 2021

Effectiveness and cost of bisphosphonate therapy in tumor bone disease

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21383

7 January 2021

Therapeutic benefit of bisphosphonates in the management of prostate cancer-related bone disease

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21383

7 January 2021

Proven efficacy of zoledronic acid in the treatment of bone metastases in patients with breast cancer and other malignancies

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21383

7 January 2021

Zoledronic acid: a review of its use in the management of bone metastases and hypercalcaemia of malignancy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21383

7 January 2021

Prognostic factors in Ewing's tumor of bone: analysis of 975 patients from the European Intergroup Cooperative Ewing's Sarcoma Study Group

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21383

7 January 2021

Reversal of multidrug resistance in murine fibrosarcoma cells by thioxanthene flupentixol

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21383

7 January 2021

Zoledronic acid delays the onset of skeletal-related events and progression of skeletal disease in patients with advanced renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21383

7 January 2021

Zoledronic acid for the treatment of bone metastases in patients with breast cancer and other solid tumors

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21383

7 January 2021

Bisphosphonates pamidronate and zoledronic acid stimulate osteoprotegerin production by primary human osteoblasts.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21383

7 January 2021

Nitrogen containing bisphosphonates induce apoptosis and inhibit the mevalonate pathway, impairing Ras membrane localization in prostate cancer cells

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21383

7 January 2021

The nitrogen-containing bisphosphonate, zoledronic acid, influences RANKL expression in human osteoblast-like cells by activating TNF-alpha converting enzyme (TACE).

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21383

7 January 2021

Zoledronic acid delays the onset of skeletal-related events and progression of skeletal disease in patients with advanced renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21383

7 January 2021

Bisphosphonates regulate cell growth and gene expression in the UMR 106-01 clonal rat osteosarcoma cell line

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21383

7 January 2021

Identifiers

DOI

10.1002/CNCR.21383

1 reference

24 December 2017

1 reference

24 December 2017